Equities brokerages forecast Pfizer Incorporated (NYSE PFE) to post quarterly sales valuing at $17.67 Bn for the present fiscal quarter. Estimates have been provided by 4 analysts. The estimates range between $15.30 Bn and $19.05 Bn. In the same period last year, quarterly sales worth $11.80 Bn were posted. The next results of its earnings are going to be posted on 27th July, Tuesday.
Detailed Overview Of PFE Stock
The latest data of PFE’s quarterly earnings were posted on 4th May, Tuesday. An EPS of $0.93 was reported, topping the consensus $0.78 estimate. Along with that, a 22.09% net margin and a 24.55% equity return were reported. The revenue for the quarter stood at $14.58.
Several research analysts have issued their reports on PFE. JPMorgan Chase & Co gave a price target of $40 while issuing a rating of “neutral” on 24th May, Monday. Berenburg Bank restated its rating of “neutral” while giving a price target of $38 on 23rd March, Tuesday. Mizuho restated its rating of “neutral” while giving a target price of $42 on 12th May, Wednesday. Royal Bank of Canada began covering PFE on 7th April, Wednesday. They issued a rating of “sector perform” while giving a price target of $42. SVB Leering upped its price target to $43 from $39 while issuing a rating of “market perform” on 5th May, Wednesday.
Jennifer B. Damco, the SVP, sold off 2,500 shares on 5th May, Wednesday at an average $40.82 price per share. DF Dent & Co. Inc., Detalus Advisors LLC, Carmichael Hill & Associates Inc., Benjamin Edwards Inc., and Baystate Wealth Management LLC all lifted their stakes in the shares.
On Friday, PFE shares opened at a value of $40.68. The quick and current ratios stand at 1.16 and 1.48 respectively. The highest and lowest values over a period of 1 year are $43.08 and $31.61 respectively. The moving average over a period of 50 days stands at $38.76.
